Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of KIRIM-KONGO-VAX in Healthy Volunteers
NCT03020771Phase 1Completed
- Sponsor
- The Scientific and Technological Research Council of Turkey
- Start
- Dec 2014
- Primary completion
- Jun 2017
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial of KIRIM-KONGO-VAX in Crimean–Congo hemorrhagic fever (CCHF) (6 arms), sponsored by The Scientific and Technological Research Council of Turkey. Primary endpoint: Safety of the IMP at 1 year. Started Dec 2014; status: completed.
02
Drugs
KIRIM-KONGO-VAX
03
Conditions
Crimean–Congo hemorrhagic fever (CCHF)
Beyond the preview
Go deeper on NCT03020771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020771.